Aktuellt
SENASTE
Management announced it is raising SEK 75m, or c. 6.6% of the market cap, to fund a phase 2 trial for lead product FG001 in new indications; to prepare for a possible phase 3 trial in 2022; for preclinical trials on FG002, which is likely to be directed at colorectal cancer; and for general corporate purposes.
LÄS MER
